Two US exchange-traded fund applications tied to Injective are moving forward, according to filings tracked this week. The applications are still working their way through the regulatory process, but their progress puts INJ in a small group of tokens now attached to live ETF paperwork.
That matters for one straightforward reason: an ETF gives traditional brokerage customers a way to get exposure without ever touching a wallet or an exchange account. For a token like INJ, that's a different audience than the one it's had so far.
What's actually advancing
Two separate applications. Both relate to Injective, the layer-1 network built around its own on-chain order book infrastructure. The filings have cleared an early stage of the review process, which keeps them alive rather than parked or withdrawn.
It's worth being precise about what this isn't. Advancing is not approval. It means the paperwork is in motion and the clock, whatever clock applies here, is running. Plenty of applications have gotten this far and died later.
Why INJ gets a second look
Injective doesn't sit in the same bucket as the majors. It isn't one of the assets that already has a spot ETF trading in the US. So two applications moving at once is a meaningful shift in how the token is treated by product issuers, even before any decision comes down.
If either one clears, the demand side changes. Not dramatically on day one, but structurally over time. Asset managers build model portfolios around products they can actually buy and custody. A token without an ETF wrapper is invisible to that process. One with it isn't.
The larger ETF pipeline
These two filings don't exist in a vacuum. They're part of a broader wave of crypto ETF applications that has been building through 2026, as issuers test how far the current regulatory posture will stretch. Every advance in that pipeline gets read as a signal about what the SEC is willing to look at, not just what it's willing to approve.
That's why even mid-cap tokens get attention when their paperwork moves. The question isn't only whether Injective gets a product. It's whether the door is opening wider for the next batch of names behind it.
What's still unresolved
The applications are advancing, but there's no decision date attached to either one in the filings reviewed. No approval, no denial, no clear timetable. The next concrete step is whatever the regulator does with the paperwork next, and until that happens, the advance itself is the only hard fact on the table.
For now, INJ has two live applications and a spot in a queue that keeps getting longer. That's the whole story. The rest is waiting.
